Tradename | Company | Number | Date | Products |
---|---|---|---|---|
PRIMAXIN | Merck & Co | N-050587 RX | 1985-11-26 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
RECARBRIO | Merck & Co | N-212819 RX | 2019-07-16 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
imipenem and cilastatin | ANDA | 2025-01-16 |
imipenem and cilastatin imipenem and cilastatin | ANDA | 2022-10-11 |
primaxin | ANDA, New Drug Application | 2024-07-05 |
recarbrio | New Drug Application | 2024-10-28 |
Expiration | Code | ||
---|---|---|---|
CILASTATIN SODIUM / IMIPENEM / RELEBACTAM, RECARBRIO, MSD MERCK CO | |||
2029-07-16 | GAIN | ||
2024-07-16 | NCE |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Cilastatin Sodium / Imipenem / Relebactam, Recarbrio, Msd Merck Co | |||
8487093 | 2029-11-19 | DS, DP | U-2586, U-2587, U-2840 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Infections | D007239 | EFO_0000544 | — | 2 | 3 | 3 | 2 | — | 9 |
Communicable diseases | D003141 | — | — | 2 | 3 | 3 | 1 | — | 8 |
Bacterial infections | D001424 | — | A49 | 1 | 1 | 2 | 1 | — | 4 |
Pneumonia | D011014 | EFO_0003106 | J18 | — | — | 2 | 1 | — | 3 |
Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | — | 2 | 1 | — | 3 |
Gram-negative bacterial infections | D016905 | — | — | 1 | 1 | 1 | 1 | — | 3 |
Sepsis | D018805 | EFO_0001420 | A41.9 | 1 | — | — | 1 | — | 2 |
Enterobacteriaceae infections | D004756 | EFO_1001313 | — | — | — | — | 1 | — | 1 |
Critical illness | D016638 | — | — | — | — | — | 1 | — | 1 |
Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 1 | 1 | — | — | 2 |
Intraabdominal infections | D059413 | — | — | — | 1 | 1 | — | — | 2 |
Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | 1 | — | — | 1 |
Iatrogenic disease | D007049 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | 1 | — | — | — | 1 |
Hematologic neoplasms | D019337 | — | — | — | 1 | — | — | — | 1 |
Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
Drug common name | Cilastatin |
INN | cilastatin |
Description | Cilastatin inhibits the human enzyme dehydropeptidase.
|
Classification | Small molecule |
Drug class | enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC1(C)C[C@@H]1C(=O)N/C(=C\CCCCSC[C@H](N)C(=O)O)C(=O)O |
PDB | — |
CAS-ID | 82009-34-5 |
RxCUI | — |
ChEMBL ID | CHEMBL766 |
ChEBI ID | 3697 |
PubChem CID | 5280454 |
DrugBank | DB01597 |
UNII ID | 141A6AMN38 (ChemIDplus, GSRS) |